38940-62-4

Usage

Uses

Used in Pharmaceutical Industry:
3-Acetyl-5-bromopyridine is used as a key intermediate in the synthesis of benzimidazole CYP11B2 inhibitors. These inhibitors are potent and selective aldosterone blockers, which play a crucial role in treating diseases that result in the stiffening of the heart, such as heart failure and hypertension.

InChI:InChI=1/C7H6BrNO/c1-5(10)6-2-7(8)4-9-3-6/h2-4H,1H3

Upstream product

• 20986-40-7 ethyl 5-bromo-3-pyridinecarboxylate 
• 141-78-6 ethyl acetate 
• 75-16-1 methylmagnesium bromide 
• 39620-02-5 5-bromonicotinoyl chloride 
• 105-53-3 diethyl malonate 
• 183608-47-1 N-methyl-N-methoxy-5-bromopyridine-3-carboxamide 
• 20826-04-4 5-bromo-3-pyridinecarboxylic acid 
• 59-67-6 nicotinic acid 

Downstream Products

• 59936-01-5 3-Acetyl-5-bromopyridine ethylene ketal 
• 142337-95-9 5-bromo-3-ethylpyridine 
• 1032314-43-4 5-(phenyl)-3-acetylpyridine 
• 283608-66-2 1-(5-bromo-pyridin-3-yl)-ethanol 
• 40472-88-6 3-bromo-5-(hydroxyisopropyl)pyridine 
• 1356483-54-9 5-(2-hydroxypropan-2-yl)pyridine-3-carbaldehyde 
• 1356483-62-9 N-[2-(cyclopropylamino)-4,5-difluorophenyl]-5-(2-hydroxypropan-2-yl)pyridine-3-carboxamide 
• 1381780-93-3 (Z)-4-chloro-3-(2-oxo-2-(5-phenylpyridin-3-yl)ethylidene)indolin-2-one 
• 1393709-29-9 5-(5-acetylpyridin-3-yl)-thiophene-2-carbonitrile 
• 1393709-32-4 1-[5-(5-acetylpyridin-3-yl)-4-chlorothiophen-2-yl]-ethanone 
• 886374-05-6 (rac)-1-(5-bromo-pyridin-3-yl)-ethylamine 
• 1108724-32-8 3-bromo-5-(1,1-difluoroethyl)pyridine 
• 1103862-13-0 1-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyridin-3-yl]-ethanone 
• 956608-45-0 N-{5-[5-(diphenylmethyleneamino)pyridin-3-yl]-1-methyl-1H-pyrazol-3-yl}acetamide 

Relevant academic research and scientific papers

DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds. These compounds are useful for therapy or prophylaxis in a mammal, and in particular as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.

NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

AMIDE DERIVATIVE AND MEDICINE

The present invention is directed to an amide derivative having excellent BCR-ABL tyrosine kinase inhibitory activity, or a salt thereof. The present invention provides an amide derivative represented by the following general formula [1]: (wherein R1 represents -CH2-R11, etc.; R2 represents alkyl, halogen, haloalkyl, etc.; R3 represents hydrogen, etc.; Het1 represents a group of the formula [6] as above, etc.; and Het2 represents pyrimidinyl, etc.), or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

AMIDE DERIVATIVE

The present invention provides an amide derivative represented by the following general formula (1): wherein R1 represents a saturated cyclic amino group, R2 represents alkyl, halogen or haloalkyl, R3 represents hydrogen or halogen, Het 2 represents pyridyl or pyrimidinyl, and Het 1 represents a group of the formula [6], or a salt thereof, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention is useful as a BCR-ABL tyrosine kinase inhibitor.

METHOD OF PREPARING INHIBITORS OF PHOSPHODIESTERASE-4

In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula V, which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula

1-biaryl-1,8-naphthyridin-4-one phosphodiesterase-4 inhibitors

Compounds represented by Formula (I): or a pharmaceutically acceptable salt thereof, are phosphodiesterrase 4 inhibitors useful in the treatment of asthma and inflammation.

Morpholines and morpholine-N-oxides and pharmaceutical compositions containing these compounds

The invention relates to new morpholines and morpholine-N-oxides of formula STR1 wherein the substituents are defined hereunder, which compounds have valuable pharmacological properties, namely an effect on the metabolism, preferably the effect of lowerin